Get All Access for $5/mo

A New Weight-Loss Drug Could Be a Complete Game Changer. 'Psychologically, You Don't Want to Eat.' Mounjaro, a diabetes drug used to treat obesity, is forecast to make $50 billion in sales annually.

By Jonathan Small

Opinions expressed by Entrepreneur contributors are their own.

In recent months, there has been a swelling interest in using diabetes drugs to treat weight loss.

Drugs with brand names such as Ozempic and Wegovy have become so popular with Hollywood celebrities and TikTokers; it's led to a nationwide shortage for diabetics.

But the anti-obesity drug craze is about to be rocked by another major development. The diabetes drug Mounjaro could be approved by the U.S. Food and Drug Administration (FDA) for weight loss later this year, according to manufacturer Eli Lilly. The company just completed a late-stage study of the drug for weight loss and found the participants lost more than 50 pounds in nearly 17 months.

"We have not seen this degree of weight reduction," Dr. Nadia Ahmad, Lilly's medical director of obesity clinical development, told CBS News.

Analysts predict that Mounjaro, tirzepatide generically, could become one of the biggest-selling drugs ever. Evaluate Pharma estimates as much as $50 billion in sales by 2028. To put this in perspective, Novo Nordisk, which makes Ozempic and Wegovy, reported combined sales of about $2.4 billion in 2022.

How does Mounjaro work?

Mounjaro was approved by the FDA last year to treat Type 2 diabetes. Patients take it via injection once per week. The drug works by activating two hormones naturally produced in the body that help to reduce appetite and increase feelings of fullness. It also curbs craving signals chemically sent from the gut to the brain.

"Psychologically, you don't want to eat," said Matthew Barlow, a health technology executive, told CBS News. "Now I can eat two bites of a dessert and be satisfied."

Though trials have shown the drugs to be safe, side effects include nausea and constipation.

Mounjaro isn't cheap. A monthly dose can run as much as $1,400. But if the FDA approves it for weight loss, people prescribed the medication for obesity could more easily be covered by insurance.

Jonathan Small

Entrepreneur Leadership Network® VIP

Founder, Write About Now Media

Jonathan Small is an award-winning author, journalist, producer, and podcast host. For 25 years, he has worked as a sought-after storyteller for top media companies such as The New York Times, Hearst, Entrepreneur, and Condé Nast. He has held executive roles at Glamour, Fitness, and Entrepreneur and regularly contributes to The New York Times, TV Guide, Cosmo, Details, Maxim, and Good Housekeeping. He is the former “Jake” advice columnist for Glamour magazine and the “Guy Guru” at Cosmo.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Side Hustle

This Former Starbucks Employee Started a Side Hustle That's Making More Than $70,000 a Month — and He's Not Done Yet

When Tom Saar moved to New York City, he spotted a lucrative business opportunity.

Business News

Is One Company to Blame for Soaring Rental Prices in the U.S.?

The FBI recently raided a major corporate landlord while investigating a rent price-fixing scheme. Here's what we know.

Business News

Amazon Has a Blank Book Problem: Buyers Report Receiving Fakes of Bestselling UFO Book

The book looked fine on the outside, but the inside was out-of-this-world.

Business News

Paramount Leadership Alludes to Layoffs If Merger Does Not Go Through

Paramount is awaiting approval on its merger with Skydance Media from majority shareholder Shari Redstone.

Business News

Microsoft Reportedly Lays Off Over 1,500 Employees in Cloud Sector as Partnership with OpenAI Strengthens

Alphabet also reportedly laid off employees from several teams in Google's cloud unit last week.

Marketing

6 SEO Tips to Help You Rank in the New Era of Quality Content

What is the best SEO strategy after Google's March 2024 core update? Here's what you need to know.